This photograph shows a KwikPen of the drug Mounjaro, containing the active ingredient tirzepatide, used in the treatment of obesity, at the Valenciennes Hospital Centre (Centre Hospitalier de Valenciennes) in Valenciennes, northern France on June 12, 2026. Virginie hopes she’s on the brink of “a life change”: starting on June 15, 2026, many patients like her will be able to access Mounjaro and Wegovy, two anti-obesity medications that are now reimbursed, and requests are already pouring in at the specialized center in Valenciennes, northern France. (Photo by Sameer Al-DOUMY / AFP via Getty Images)

( NewsNation ) — The FDA has issued a recall for 23 GLP-1 compounded vials from Apothecary Pharma LLC due to lack of assurance the vials are sterile.

The FDA has designated the recall as Class II , meaning exposure to the products could cause reversible or temporary health consequences and poses little risk of serious consequences from use, according to the FDA website.

What products to look out for:

The…